PharmaNutra S.p.A. Strengthens its Position in North America
The recent distribution agreement reached with Sigma Lifesciences marks a crucial step for the Italian company, PharmaNutra S.p.A., solidifying its foothold in North America. This agreement underscores the company’s continued growth in a market where it already has a subsidiary, PharmaNutra USA Corp.
Announcement of the Distribution Agreement
PharmaNutra S.p.A. (MTA; Ticker PHN), known for its innovative nutritional supplements aimed at improving health, recently announced an exciting new partnership. Sigma Lifesciences, a reputable Canadian pharmaceutical company, will aid in distributing four distinct health products across Canada, which further expands the reach of PharmaNutra's offerings that are already available in over 80 countries.
Details of the Health Products
Under the agreement, Sigma Lifesciences will manage the distribution of the SiderAL® product line, which includes SiderAL® Forte, SiderAL® Folic, and SiderAL® Drops. These dietary supplements harness the power of Sucrosomial® Iron, utilizing advanced Sucrosomial® Technology that dramatically enhances the absorption and tolerance of micronutrients, specifically iron.
Strategic Marketing Plans
As part of an elaborate marketing strategy, the launch of these SiderAL® products is anticipated in the second quarter of 2025, with an initial focus on SiderAL® Forte. Recently, a training session was conducted for Sigma Lifesciences' team in Toronto, led by the scientific and commercial management team from PharmaNutra. This session included a Focus Group gathering over thirty Canadian healthcare professionals, covering various specialties such as Gynecology, Hematology, Internal Medicine, and Oncology, aimed at training and understanding local market requirements.
Additional Offerings from PharmaNutra
Alongside the SiderAL® products, Sigma Lifesciences will also distribute Ultramag®, which is a dietary supplement based on Sucrosomial® Magnesium. Both Ultramag® and the SiderAL® products have gained official approval from Health Canada, allowing for their commercialization within the country.
Insights from PharmaNutra's COO
COO Carlo Volpi shared insights regarding the partnership with Sigma Lifesciences, emphasizing the significance of this agreement in enhancing their presence in North America. He expressed optimism about the potential of the Canadian market and confidence in the advanced technologies behind PharmaNutra's products. Volpi stated, "We are truly confident about the impact that our products, based on innovative patented technologies, can have in the region. The contribution of our partner, Sigma Lifesciences, a renowned and relevant player, will play a crucial role in the development of our business in Canada."
For inquiries or more information, PharmaNutra can be reached through their Investor Relations department or the dedicated contacts provided.
Frequently Asked Questions
What is the significance of the distribution agreement?
The agreement enhances PharmaNutra's presence in North America, marking a strategic expansion into Canada.
What products are included in this distribution agreement?
The agreement includes SiderAL® Forte, SiderAL® Folic, SiderAL® Drops, and Ultramag®.
When will the products be launched in Canada?
The marketing campaign for these products is set to launch in the second quarter of 2025.
Who conducted the training session for Sigma Lifesciences?
The training session was facilitated by the Scientific and Commercial Management of PharmaNutra.
What technology do SiderAL® products utilize?
SiderAL® products utilize Sucrosomial® Technology, enhancing the absorption of iron and improving tolerability.
